For your patients with bone metastases from solid tumors, offer the
proven efficacy of XGEVA® in a single subcutaneous injection once every 4 weeks.1

See how XGEVA® can help prevent skeletal-related events in your patients with bone metastases from:

Indication

XGEVA® (denosumab) is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors.

XGEVA® is not indicated for the prevention of skeletal-related events in patients with multiple myeloma.

Important Safety Information

Hypocalcemia Hypersensitivity Drug Products with Same Active Ingredient Osteonecrosis of the Jaw Atypical Subtrochanteric and Diaphyseal Femoral Fracture Embryo-Fetal Toxicity Adverse Reactions Please see Full Prescribing Information

References

  1. Xgeva® (denosumab) prescribing information, Amgen.

    Note: The Amgen FIRST STEP Program MasterCard is issued by The Bancorp Bank pursuant to license by MasterCard International and this card may not be used everywhere Debit MasterCard is accepted. No cash or ATM access. MasterCard is a registered trademark of MasterCard International Incorporated. The Bancorp Bank; Member FDIC.